Journal List > Immune Netw > v.1(2) > 1033222

TOOLS
Shin, Lim, Choi, Lee, Noh, Ryu, Lee, Bang, Park, and Jin: Study of plasma transforming growth factor-β 1 level as a useful tumor marker in various cancers
Original Article

Immune Network 2001; 1(2): 143-150.

Published online: 31 August 2001

DOI: https://doi.org/10.4110/in.2001.1.2.143

Study of plasma transforming growth factor-β 1 level as a useful tumor marker in various cancers

Hoon Shin, Chang Ki Lim, In Young Choi, Doo Yun Lee1, Dong Yong Noh2, Min Hee Ryu3, Hyo Suk Lee4, Yung Jue Bang3, Jong Sup Park5, Seung Won Jin

Central Research Institute, Hanmi Pharmaceutical Co., Ltd., Seoul, Korea.

1Department of Thoracic and Cardiovascular Surgery, Respiratory Center, Yongdong Severance Hospital, College of Medicine, Yonsei University, Seoul, Korea.

2Department of General Surgery, Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea.

3Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea.

4Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul National University, Korea.

5Department of Obstetrics and Gynecology, Catholic University Medical College, Seoul, Korea.

Corresponding Author (swjin@hanmi.co.kr)

Copyright © 2001 The Korean Association of Immunologists

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Many investigators have found transforming growth factor-β1 (TGF-β1) to be elevated in tumors. Changes in responsiveness to TGF-β1 have been linked to malignant transformation, tumor progression and tumor regression. Many malignant cell lines of epithelial or hematopoietic origin are refractory to the antiproliferative effects of TGF-β1. However, a little is known about the association of TGF-β1 with progression of malignant tumor.

Methods

In this study, we measured the plasma level of TGF-β1 in various cancer patients and evaluated the utility of plasma TGF-β1 as a possible tumor marker. Plasma TGF-β1 levels were measured using enzyme-linked immunosorbent assay in cancer patients and normal controls. Carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) as tumor marker were compared with TGF-β1 in the aspects of sensitivity and specificity.

Results

The mean of plasma TGF-β1 levels was 1.2 19 ± 0.834 ng/ml in normal controls, 5.491 ± 3.598 ng/ml in breast cancer, 12.670 ± 10.386 ng/ml in lung cancer, 5.747 ± 3.228 ng/ml in hepatocellular carcinoma and 10.854 ± 7.996 ng/ml in cervical cancer. In comparison with CEA and AFP, TGF-β1 is more sensitive.

Conclusion

We conclude that the high levels of TGF-β1 are common in the plasma of cancer patients. These results suggest that the plasma TGF-β1 level can be a potent tumor marker in various cancer patients.

Keywords: carcinoembryonic antigen(CEA), alpha-fetoprotein(AFP), cervical cancer, enzyme-linked immuno-sorbent assay(ELISA), transforming growth factor-β1(TGF-β1), tumor marker

TOOLS
Similar articles